Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-12-01

FDA Approved: ZYRTEC HIVES — Supplemental Application (Kenvue Brands LLC)

View source ↗

Summary

FDA approved a supplemental application to expand ZYRTEC HIVES labeling for the treatment of urticaria (hives) with cetirizine hydrochloride, under Kenvue Brand…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ZYRTEC HIVES (cetirizine hydrochloride)

Snippet

SUPPL AP for ZYRTEC HIVES (CETIRIZINE HYDROCHLORIDE)